GURUFOCUS.COM » STOCK LIST » Basic Materials » Agriculture » ACI Formulations Ltd (DHA:ACIFORMULA) » Definitions » EBIT

ACI Formulations (DHA:ACIFORMULA) EBIT : BDT620 Mil (TTM As of Dec. 2023)


View and export this data going back to 2008. Start your Free Trial

What is ACI Formulations EBIT?

ACI Formulations's earnings before interest and taxes (EBIT) for the three months ended in Dec. 2023 was BDT235 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2023 was BDT620 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. ACI Formulations's annualized ROC % for the quarter that ended in Dec. 2023 was 11.91%. ACI Formulations's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was 18.91%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. ACI Formulations's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was 7.10%.


ACI Formulations EBIT Historical Data

The historical data trend for ACI Formulations's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ACI Formulations EBIT Chart

ACI Formulations Annual Data
Trend Dec13 Dec14 Dec15 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 417.63 348.67 420.21 461.88 571.18

ACI Formulations Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 210.74 149.60 75.32 159.94 235.29

Competitive Comparison of ACI Formulations's EBIT

For the Agricultural Inputs subindustry, ACI Formulations's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ACI Formulations's EV-to-EBIT Distribution in the Agriculture Industry

For the Agriculture industry and Basic Materials sector, ACI Formulations's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where ACI Formulations's EV-to-EBIT falls into.



ACI Formulations EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was BDT620 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ACI Formulations  (DHA:ACIFORMULA) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

ACI Formulations's annualized ROC % for the quarter that ended in Dec. 2023 is calculated as:

ROC % (Q: Dec. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Sep. 2023 ) + Invested Capital (Q: Dec. 2023 ))/ count )
=941.148 * ( 1 - 23.88% )/( (5941.087 + 6093.185)/ 2 )
=716.4018576/6017.136
=11.91 %

where

Invested Capital(Q: Sep. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=6769.807 - 647.986 - ( 180.734 - max(0, 3345.03 - 4213.145+180.734))
=5941.087

Invested Capital(Q: Dec. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=7136.231 - 835.507 - ( 207.539 - max(0, 3708.062 - 4558.537+207.539))
=6093.185

Note: The Operating Income data used here is four times the quarterly (Dec. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

ACI Formulations's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2023 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2023  Q: Dec. 2023
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=941.148/( ( (2510.848 + max(2517.976, 0)) + (2531.88 + max(2391.397, 0)) )/ 2 )
=941.148/( ( 5028.824 + 4923.277 )/ 2 )
=941.148/4976.0505
=18.91 %

where Working Capital is:

Working Capital(Q: Sep. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(1411.451 + 1340.739 + 435.592) - (647.986 + 0 + 21.82)
=2517.976

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(1603.953 + 1125.175 + 517.13) - (835.507 + 0 + 19.354)
=2391.397

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

ACI Formulations's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2023 )
=620.149/8737.823
=7.10 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ACI Formulations EBIT Related Terms

Thank you for viewing the detailed overview of ACI Formulations's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


ACI Formulations (DHA:ACIFORMULA) Business Description

Traded in Other Exchanges
N/A
Address
ACI Centre, 245, Tejgaon Industrial Area, Dhaka, BGD, 1208
ACI Formulations Ltd is an agricultural chemicals manufacturer. The principal activities of the company are manufacturing and marketing a number of agrochemical and consumer products. The company has structured its operations into the following business segments - Crop Care and Public Health segment, which manufactures and sell crop care and public health products; Mosquito Coil segment is engaged in the manufacturing and selling of mosquito coil products; the Aerosol segment is engaged in the manufacturing and selling aerosol and air freshener products; and Paint segment which manufactures and sells paint products. It derives key revenue from the Crop Care and Public Health segment.

ACI Formulations (DHA:ACIFORMULA) Headlines

No Headlines